Hong Kong innovative drug stocks continue to recover, Hang Seng Healthcare ETF Huaxia (159892) 冲击 three consecutive gains

On July 22, the three major indices in the Hong Kong stock market adjusted, while the innovative drug sector rose against the trend, demonstrating strong resilience. The Hang Seng Healthcare ETF Huaxia (159892) rose more than 2% during trading, with companies such as Insilico Medicine, Akeso, and Ascentage Pharma leading the gains.

Notably, this ETF had risen for two consecutive trading days prior to this, showing certain anti-drop attributes and repair momentum. As an ETF product supporting T+0 trading, its latest scale has exceeded 4.9 billion yuan, with good liquidity.

The Hang Seng Healthcare ETF Huaxia (159892) tracks the Hang Seng Biotechnology Index, which aims to reflect the performance of 30 biotechnology companies listed in Hong Kong that meet the Stock Connect eligibility criteria, representing the largest scale and best liquidity.

Its constituent stocks not only cover traditional pharmaceutical leaders but also specifically include unprofitable biotechnology companies listed under Rule 18A of the HKEX listing rules. These companies often possess unique R&D pipelines and core technologies, possessing high growth potential, serving as an important window for investors to layout in the innovative drug track.